Circumcision plus antibiotic, anti-inflammatory, and α-blocker therapy for the treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, multicenter trial
- 1 July 2014
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 33 (5) , 617-622
Abstract
The purpose of the study was to evaluate the efficacy of circumcision combined with antibiotic, anti-inflammatory, and α-blocker therapy for the treatment for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Subjects assigned to the circumcision group were given antibiotic, anti-inflammatory, and α-blocker medications and scheduled for surgery the same period in each site by study clinicians. Subjects assigned to the control group were asked to only take the same medications and remain uncircumcised until the end of the 3-month study period. The primary outcome was a reduction of at least four points on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). A total of 774 eligible participants underwent randomization, and the ratio of men with a decrease of at least four points on the total NIH-CPSI score from baseline to 12 weeks was 84.6 % in the circumcision group and 68.5 % in the control group (P < 0.001). Of the 713 men who completed the trial, the median total NIH-CPSI score decreased significantly from 21.0 ± 7.0 to 12.0 ± 8.0 (P < 0.001) in the circumcision group, and in the control group, the change was from 21.0 ± 8.0 to 15.0 ± 7.0 (P < 0.001). Comparison of the changes in the total and three subdomain NIH-CPSI scores over time revealed significant differences between the circumcision and control groups (P < 0.001). Our findings show that circumcision plus antibiotic, anti-inflammatory, and α-blocker therapy for CP/CPPS patients resulted in improved NIH-CPSI scores compared with medication therapy only.Keywords
This publication has 29 references indexed in Scilit:
- α‐blockers, antibiotics and anti‐inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndromeBJU International, 2012
- Silodosin for Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Results of a Phase II Multicenter, Double-Blind, Placebo Controlled StudyJournal of Urology, 2011
- HIV-1 Efficient Entry in Inner Foreskin Is Mediated by Elevated CCL5/RANTES that Recruits T Cells and Fuels Conjugate Formation with Langerhans CellsPLOS Pathogens, 2011
- Enhanced cellular responses and environmental sampling within inner foreskin explants: implications for the foreskin's role in HIV transmissionMucosal Immunology, 2010
- T-Cell Recognition of Prostatic Peptides in Men With Chronic Prostatitis/Chronic Pelvic Pain SyndromeJournal of Urology, 2009
- Foreskin surface area and HIV acquisition in Rakai, Uganda (size matters)AIDS, 2009
- Alfuzosin and Symptoms of Chronic Prostatitis–Chronic Pelvic Pain SyndromeNew England Journal of Medicine, 2008
- Human immunodeficiency virus‐1 acquisition in genital mucosa: Langerhans cells as key‐playersJournal of Internal Medicine, 2008
- Langerhans cells and viral immunityEuropean Journal of Immunology, 2008
- Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagementJournal of Experimental Medicine, 2006